Cost-effectiveness of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) testing and isolation strategies in nursing homes

被引:2
|
作者
Bartsch, Sarah M. [1 ,2 ,3 ]
Weatherwax, Colleen [1 ,2 ,3 ]
Martinez, Marie F. [1 ,2 ,3 ]
Chin, Kevin L. [1 ,2 ,3 ]
Wasserman, Michael R. [4 ,5 ]
Singh, Raveena D. [6 ]
Heneghan, Jessie L. [1 ,2 ,3 ]
Gussin, Gabrielle M. [6 ]
Scannell, Sheryl A. [1 ,2 ,3 ]
White, Cameron [1 ,2 ,3 ]
Leff, Bruce [7 ]
Huang, Susan S. [6 ]
Lee, Bruce Y. [1 ,2 ,3 ,8 ]
机构
[1] CUNY, Ctr Adv Technol & Commun Hlth CATCH, Grad Sch Publ Hlth & Hlth Policy, New York, NY 10027 USA
[2] CUNY, Publ Hlth Informat Computat & Operat Res PHICOR, Grad Sch Publ Hlth & Hlth Policy, New York, NY 10027 USA
[3] CUNY, Artificial Intelligence Modeling Informat Nutr Gui, Grad Sch Publ Hlth & Hlth Policy, New York, NY 10027 USA
[4] Los Angeles Jewish Home, Reseda, CA USA
[5] Calif Assoc Long Term Care Med, Santa Clarita, CA USA
[6] Univ Calif Irvine, Div Infect Dis, Sch Med, Irvine, CA USA
[7] Johns Hopkins Univ, Ctr Transformat Geriatr Res, Div Geriatr Med, Sch Med, Baltimore, MD USA
[8] CUNY, New York City Pandem Response Inst PRI, Grad Sch Publ Hlth & Hlth Policy, New York, NY 10027 USA
基金
美国医疗保健研究与质量局;
关键词
COVID-19; EFFICACY; OUTCOMES;
D O I
10.1017/ice.2024.9
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objective: Nursing home residents may be particularly vulnerable to coronavirus disease 2019 (COVID-19). Therefore, a question is when and how often nursing homes should test staff for COVID-19 and how this may change as severe acute respiratory coronavirus virus 2 (SARS-CoV-2) evolves.Design: We developed an agent-based model representing a typical nursing home, COVID-19 spread, and its health and economic outcomes to determine the clinical and economic value of various screening and isolation strategies and how it may change under various circumstances.Results: Under winter 2023-2024 SARS-CoV-2 omicron variant conditions, symptom-based antigen testing averted 4.5 COVID-19 cases compared to no testing, saving $191 in direct medical costs. Testing implementation costs far outweighed these savings, resulting in net costs of $990 from the Centers for Medicare & Medicaid Services perspective, $1,545 from the third-party payer perspective, and $57,155 from the societal perspective. Testing did not return sufficient positive health effects to make it cost-effective [$50,000 per quality-adjusted life-year (QALY) threshold], but it exceeded this threshold in >= 59% of simulation trials. Testing remained cost-ineffective when routinely testing staff and varying face mask compliance, vaccine efficacy, and booster coverage. However, all antigen testing strategies became cost-effective (<=$31,906 per QALY) or cost saving (saving <=$18,372) when the severe outcome risk was >= 3 times higher than that of current omicron variants.Conclusions: SARS-CoV-2 testing costs outweighed benefits under winter 2023-2024 conditions; however, testing became cost-effective with increasingly severe clinical outcomes. Cost-effectiveness can change as the epidemic evolves because it depends on clinical severity and other intervention use. Thus, nursing home administrators and policy makers should monitor and evaluate viral virulence and other interventions over time.
引用
收藏
页码:754 / 761
页数:8
相关论文
共 50 条
  • [21] The landscape of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genomic mutations
    Lippi, Giuseppe
    Henry, Brandon M.
    JOURNAL OF LABORATORY AND PRECISION MEDICINE, 2022, 7
  • [22] Smoking and the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection
    Lee, Sang Chul
    Son, Kang Ju
    Kim, Dong Wook
    Han, Chang Hoon
    Choi, Yoon Jung
    Kim, Seong Woo
    Park, Seon Cheol
    NICOTINE & TOBACCO RESEARCH, 2021, 23 (10) : 1787 - 1792
  • [23] Immunological and virological aspects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and hepatitis C virus
    Leon, Fabiola Justina Fumero
    da Silva, Lucas Lima
    Santos, Alanna Calheiros
    Duarte da Costa, Vanessa
    Miguel, Juliana Custodio
    Marques, Julia Trece
    Nascimento, Giselle Prado
    Ferreira da Silva, Elisangela
    Lewis-Ximenez, Lia Laura
    Villar, Livia Melo
    de Paula, Vanessa Salete
    JOURNAL OF MEDICAL VIROLOGY, 2022, 94 (05) : 2296 - 2301
  • [24] Implications of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Pandemic on the Epidemiology of Pediatric Respiratory Syncytial Virus Infection
    Odumade, Oludare A.
    van Haren, Simon D.
    Angelidou, Asimenia
    CLINICAL INFECTIOUS DISEASES, 2022, 75 (SUPPL 1) : S130 - S135
  • [25] Diagnostic Strategies of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: Operational Recommendations for Health Professionals
    Zrieq, Rafat
    Khemakhem, Asma M.
    Haouas, Najoua
    Zeariya, Mohammed G. M.
    Alshammari, Fares
    Algahtani, Fahad D.
    JOURNAL OF PHARMACEUTICAL RESEARCH INTERNATIONAL, 2021, 33 (38B) : 210 - 223
  • [26] Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and Middle East Respiratory Syndrome Coronavirus (MERS-CoV) coinfection: A unique case series
    Elhazmi, Alyaa
    Al-Tawfiq, Jaffar A.
    Sallam, Hend
    Al-Omari, Awad
    Alhumaid, Saad
    Mady, Ahmad
    Al Mutair, Abbas
    TRAVEL MEDICINE AND INFECTIOUS DISEASE, 2021, 41
  • [27] A comparative review of pathogenesis and host innate immunity evasion strategies among the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV)
    Noor, Rashed
    ARCHIVES OF MICROBIOLOGY, 2021, 203 (05) : 1943 - 1951
  • [28] Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection: let the virus be its own demise
    Nemunaitis, John
    Stanbery, Laura
    Senzer, Neil
    FUTURE VIROLOGY, 2020, 15 (06) : 381 - 395
  • [29] Detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) RNA in the Human Eye
    Kamalipour, Alireza
    Ashraf, Mohammad Ali
    Moghimi, Sasan
    Moattari, Afagh
    Ashraf, Mohammad Javad
    Abbasi, Farhad
    Azodi, Farzan
    Oboudi, Shadi
    Pirbonyeh, Neda
    Mokhtaryan, Maryam
    Roshanshad, Amirhossein
    Do, Jiun L.
    Weinreb, Robert N.
    OCULAR IMMUNOLOGY AND INFLAMMATION, 2023, 31 (01) : 32 - 38
  • [30] The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Epidemic in Zimbabwe: Quo Vadis?
    Katsidzira, Leolin
    Gwaunza, Lenon
    Hakim, James G.
    CLINICAL INFECTIOUS DISEASES, 2020, 71 (16) : 2180 - 2183